Company Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases.
Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.
The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver.
It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.
Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Jun 17, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 255 |
| CEO | Dr. Sekar Kathiresan M.D. |
Contact Details
Address: 500 Technology Square Cambridge, Massachusetts United States | |
| Website | https://www.vervetx.com |
Stock Details
| Ticker Symbol | VERV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840574 |
| CUSIP Number | 92539P101 |
| ISIN Number | US92539P1012 |
| Employer ID | 82-4800132 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sekar Kathiresan M.D. | Co-Founder, Chief Executive Officer & Director |
| Allison Dorval CPA | Chief Financial Officer & Principal Accounting Officer |
| Andrew D. Ashe J.D. | President, Chief Operating Officer & General Counsel |
| Dr. Anthony Philippakis M.D., Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Barry S. Ticho FACC, M.D., Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Dr. Kiran Musunuru M.D., M.P.H., Ph.D. | Co-Founder |
| Dr. Troy Lister Ph.D. | Chief Scientific Officer |
| Issi Rozen M.B.A. | Co-Founder & Strategic Advisor |
| Joan Nickerson M.B.A. | Chief Administrative Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 04, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 05, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 8-K | Current Report |
| Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |